Literature DB >> 33330816

Screening for dental focal infections in febrile patients with hematologic malignancies who received chemotherapy: a retrospective cohort study.

Yasuyuki Shimada1, Yohei Kawasaki2,3, Ryo Nasu4, Fumihiko Nakamura4, Yutaka Maruoka1,5.   

Abstract

Source of fever in chemotherapy patients is often unknown. Fever can also be fatal. No observational studies have determined the incidence of dental focal infection (DFI)-associated fever, despite oral cavity being a potential source of infection. We report the incidence of fever after chemotherapy in patients with hematological malignancies and their association with DFIs in 441 patients visiting our institution during a 6-year period. Dental treatments, including tooth extraction, were performed, and their oral and hematological profiles were monitored after chemotherapy. Fever was evident in 87 (38.5%) of 226 patients (≥ 38˚C) after the first cycle of chemotherapy. Sepsis due to DFIs (n = 4; 4.6%) was evaluated. Chemotherapy was delayed due to DFI in one case. Fever after chemotherapy should be differentiated from oral infections. Our study emphasizes the significance of DFI in patients with fever after chemotherapy and can help in improving the prognosis of patients. 2020, National Center for Global Health and Medicine.

Entities:  

Keywords:  fever; hematopoietic neoplasm; immunosuppression; infection; oral cavity

Year:  2020        PMID: 33330816      PMCID: PMC7731069          DOI: 10.35772/ghm.2019.01034

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  15 in total

Review 1.  Fever in immunocompromised hosts.

Authors:  Devang M Patel; David J Riedel
Journal:  Emerg Med Clin North Am       Date:  2013-08-17       Impact factor: 2.264

2.  Sequential Organ Failure Assessment Score Modified for Recent Infection in Patients With Hematologic Malignant Tumors and Severe Sepsis.

Authors:  Jared A Greenberg; Michael Z David; Matthew M Churpek; David L Pitrak; Jesse B Hall; John P Kress
Journal:  Am J Crit Care       Date:  2016-09       Impact factor: 2.228

3.  Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4.

Authors:  Daiki Ogawara; Minoru Fukuda; Shiro Ueno; Yoshihiro Ohue; Shinnosuke Takemoto; Kosuke Mizoguchi; Katsumi Nakatomi; Yoichi Nakamura; Yasushi Obase; Takuya Honda; Kazuhiro Tsukamoto; Kazuto Ashizawa; Mikio Oka; Shigeru Kohno
Journal:  Support Care Cancer       Date:  2015-06-25       Impact factor: 3.603

Review 4.  Evaluation of the infant with fever without source: an evidence based approach.

Authors:  M Slater; S E Krug
Journal:  Emerg Med Clin North Am       Date:  1999-02       Impact factor: 2.264

Review 5.  Catheter-related infections in patients with haematological malignancies: novel preventive and therapeutic strategies.

Authors:  Ramia Zakhour; Anne-Marie Chaftari; Issam I Raad
Journal:  Lancet Infect Dis       Date:  2016-11       Impact factor: 25.071

Review 6.  Oral sources of septicaemia in patients with malignancies.

Authors:  J H Meurman; S Pyrhönen; L Teerenhovi; C Lindqvist
Journal:  Oral Oncol       Date:  1997-11       Impact factor: 5.337

7.  Surveillance for nosocomial infections and fever of unknown origin among adult hematology-oncology patients.

Authors:  Steffen Engelhart; Axel Glasmacher; Martin Exner; Michael H Kramer
Journal:  Infect Control Hosp Epidemiol       Date:  2002-05       Impact factor: 3.254

8.  Role of procalcitonin and C-reactive protein for discrimination between tumor fever and infection in patients with hematological diseases.

Authors:  Sho Hangai; Yasuhito Nannya; Mineo Kurokawa
Journal:  Leuk Lymphoma       Date:  2014-08-18

Review 9.  Fever without apparent source on clinical examination.

Authors:  Paul L McCarthy
Journal:  Curr Opin Pediatr       Date:  2004-02       Impact factor: 2.856

10.  Importance of eliminating potential dental focal infection before the first cycle of chemotherapy in patients with hematologic malignancy.

Authors:  Yasuyuki Shimada; Yumiko Nakagawa; Kazuki Ide; Izumi Sato; Shotaro Hagiwara; Hiroshi Yamada; Yohei Kawasaki; Yutaka Maruoka
Journal:  Support Care Cancer       Date:  2017-02-27       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.